CLINICAL TRIAL: AUTOLOGOUS EBV SPECIFIC CTLS FOR THERAPY OF SEVERE CHRONIC EBV I

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 严重的慢性EBV感染综合征的发病机制可能与循环抑制因子的存在有关，这些循环抑制因子使EBV特异性T细胞的产生无法控制EBV感染，并可以通过在体外产生自体EBV特异性CTL并过继地将它们转移到接受者身上来克服。 该议定书的具体目标是 1)确定自身EBV特异性细胞毒T细胞株静脉注射在重度慢性EBV感染者中的安全性；2)确定静脉注射CTL对这些患者的抗病毒和免疫学效果；3)评估这些注射的临床效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The pathogenesis of severe chronic EBV infection syndrome may relate to the presence of circulating inhibitory factors that disable the generation of EBV-specific T cells to control EBV infection and can be overcome by generating autologous EBV specific CTL ex vivo and adoptively transferring them to the recipient. The specific objectives of this protocol are 1) To determine the safety of intravenous injections of autologous EBV specific cytotoxic T cell lines in individuals with severe chronic EBV infection, 2) To determine antiviral and immunological efficacy of intravenous injections of CTLs in these patients, 3) to assess the clinical effects of these injections.